Weekly Cisplatin-Based Chemoradiotherapy Improves RFS and OS, Although Not Statistically Significant, for Patients with Cervical Cancer and Intermediate Pathologic Risk Factors By Ogkologos - September 24, 2025 288 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NRG Oncology/GOG-263/KGOG1008 study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients... April 28, 2025 FDA Approves Crizotinib for Children and Young Adults with Relapsed or... January 19, 2021 2023 ASCO Annual Meeting Research Round Up: Improving Symptom Monitoring and... September 21, 2023 To Treat Pancreatic Cancer, Mouse Study Suggests Altering Tumor Microbiome September 9, 2019 Load more HOT NEWS 3-in-1 Approach Helps Women in Rural Areas Get Cancer Screenings More Treatment Options Emerging for Some Men with Metastatic Prostate Cancer Reunión anual de la American Society of Clinical Oncology de 2022:... New Research in Treating Metastatic Breast Cancer, Preventing Breast Cancer, and...
